Search results
Results from the Health.Zone Content Network
The most common cause of death in people with VHL disease is a type of slow-growing tumor in your central nervous system called hemangioblastoma. This type of tumor occurs in 13 to 72 percent of ...
View/Edit Mouse. The Von Hippel–Lindau tumor suppressor also known as pVHL is a protein that, in humans, is encoded by the VHL gene. Mutations of the VHL gene are associated with Von Hippel–Lindau disease, which is characterized by hemangioblastomas of the brain, spinal cord and retina. It is also associated with kidney and pancreatic lesions.
Von Hippel–Lindau disease (VHL), also known as Von Hippel–Lindau syndrome, is a rare genetic disorder with multisystem involvement. [3] It is characterized by visceral cysts and benign tumors with potential for subsequent malignant transformation. It is a type of phakomatosis that results from a mutation in the Von Hippel–Lindau tumor ...
dizziness and a loss of balance. seizures. sudden inability to speak. hearing loss. weakness or numbness that gradually worsens on one side of the body. uncharacteristic moodiness and anger. Some ...
Children up to the age of 14 with higher-grade tumors tend to survive longer than adults. About 19.4% of kids with this tumor live for five years or more. And about 26% of adolescents and young ...
The ELST has been referred to as adenocarcinoma of endolymphatic sac, Heffner tumor, [1] papillary adenomatous tumor, aggressive papillary adenoma, invasive papillary cystadenoma, and papillary tumor of temporal bone. However, these names are not encouraged as they do not accurately classify the current understanding of the tumor. [2][3]
Symptoms of neoplastic disease vary depending on where the neoplasm is located. However, there are a few symptoms that are common across types. Common symptoms of neoplastic disease include ...
The Knudson hypothesis, also known as the two-hit hypothesis, is the hypothesis that most tumor suppressor genes require both alleles to be inactivated, either through mutations or through epigenetic silencing, to cause a phenotypic change. [1] It was first formulated by Alfred G. Knudson in 1971 [2] and led indirectly to the identification of ...